|
1
|
Kyrgiou M, Athanasiou A, Paraskevaidi M,
Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P and
Paraskevaidis E: Adverse obstetric outcomes after local treatment
for cervical preinvasive and early invasive disease according to
cone depth: Systematic review and meta-analysis. BMJ.
354:i36332016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arbyn M, Kyrgiou M, Simoens C, Raifu AO,
Koliopoulos G, Martin-Hirsch P, Prendiville W and Paraskevaidis E:
Perinatal mortality and other severe adverse pregnancy outcomes
associated with treatment of cervical intraepithelial neoplasia:
Meta-analysis. BMJ. 337:a12842008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Albrechtsen S, Rasmussen S, Thoresen S,
Irgens LM and Iversen OE: Pregnancy outcome in women before and
after cervical conisation: Population based cohort study. BMJ.
337:a13432008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kreimer AR, Guido RS, Solomon D, Schiffman
M, Wacholder S, Jeronimo J, Wheeler CM and Castle PE: Human
papillomavirus testing following loop electrosurgical excision
procedure identifies women at risk for posttreatment cervical
intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol
Biomarkers Prev. 15:908–914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hildesheim A, Herrero R, Wacholder S,
Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin
G, Porras C, et al: Costa rican HPV vaccine trial group: effect of
human papillomavirus 16/18 l1 viruslike particle vaccine among
young women with preexisting infection: A randomized trial. JAMA.
298:743–753. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
FUTURE IIStudy Group, . Quadrivalent
vaccine against human papillomavirus to prevent high-grade cervical
lesions. N Engl J Med. 356:1915–1927. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Young JL, Jazaeri AA, Darus CJ and
Modesitt SC: Cyclooxygenase-2 in cervical neoplasia: A review.
Gynecol Oncol. 109:140–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim HS, Kim T, Kim MK, Suh DH, Chung HH
and Song YS: Cyclooxygenase-1 and −2: Molecular targets for
cervical neoplasia. J Cancer Prev. 18:123–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grabosch SM, Shariff OM, Wulff JL and Helm
CW: Non-steroidal anti-inflammatory agents to induce regression and
prevent the progression of cervical intraepithelial neoplasia.
Cochrane Database Syst Rev. 9:CD0041212014.
|
|
10
|
Zur Hausen H: Papillomaviruses and cancer:
From basic studies to clinical application. Nat Rev Cancer.
2:342–350. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Badaracco G and Venuti A: Human
papillomavirus therapeutic vaccines in head and neck tumors. Expert
Rev Anticancer Ther. 7:753–766. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li N, Franceschi S, Howell-Jones R,
Snijders PJ and Clifford GM: Human papillomavirus type distribution
in 30,848 invasive cervical cancers worldwide: Variation by
geographical region, histological type and year of publication. Int
J Cancer. 128:927–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tjalma WA, Fiander A, Reich O, Powell N,
Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund
M, et al: Differences in human papillomavirus type distribution in
high-grade cervical intraepithelial neoplasia and invasive cervical
cancer in Europe. Int J Cancer. 132:854–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Poelgeest MI, Welters MJ, van Esch EM,
Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den
Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, et al:
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of
patients with advanced or recurrent HPV16-induced gynecological
carcinoma, a phase II trial. J Transl Med. 11:882013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Su JH, Wu A, Scotney E, Ma B, Monie A,
Hung CF and Wu TC: Immunotherapy for cervical cancer: Research
status and clinical potential. BioDrugs. 24:109–129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hung CF, Ma B, Monie A, Tsen SW and Wu TC:
Therapeutic human papillomavirus vaccines: Current clinical trials
and future directions. Expert Opin Biol Ther. 8:421–439. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ressing ME, van Driel WJ, Brandt RM,
Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P,
Offringa R, Sette A, et al: Detection of T helper responses, but
not of human papillomavirus-specific cytotoxic T lymphocyte
responses, after peptide vaccination of patients with cervical
carcinoma. J Immunother. 23:255–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Driel WJ, Ressing ME, Kenter GG,
Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R,
Bauknecht T, Tamm-Hermelink A, et al: Vaccination with HPV16
peptides of patients with advanced cervical carcinoma: Clinical
evaluation of a phase I–II trial. Eur J Cancer. 35:946–952. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Welters MJ, Kenter GG, Piersma SJ, Vloon
AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR,
Wafelman AR, Oostendorp J, et al: Induction of tumor-specific CD4+
and CD8+ T-cell immunity in cervical cancer patients by a human
papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer
Res. 14:178–187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muderspach L, Wilczynski S, Roman L, Bade
L, Felix J, Small LA, Kast WM, Fascio G, Marty V and Weber J: A
phase I trial of a human papillomavirus (HPV) peptide vaccine for
women with high-grade cervical and vulvar intraepithelial neoplasia
who are HPV 16 positive. Clin Cancer Res. 6:3406–3416.
2000.PubMed/NCBI
|
|
21
|
Kenter GG, Welters MJ, Valentijn AR, Lowik
MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM,
Offringa R, Drijfhout JW, et al: Vaccination against HPV-16
oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med.
361:1838–1847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Vos van Steenwijk PJ, Ramwadhdoebe TH,
Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM,
Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, et al: A
placebo-controlled randomized HPV16 synthetic long-peptide
vaccination study in women with high-grade cervical squamous
intraepithelial lesions. Cancer Immunol Immunother. 61:1485–1492.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Vos van Steenwijk PJ, van Poelgeest MI,
Ramwadhdoebe TH, Löwik MJ, Berends-van der Meer DM, van der Minne
CE, Loof NM, Stynenbosch LF, Fathers LM, Valentijn AR, et al: The
long-term immune response after HPV16 peptide vaccination in women
with low-grade pre-malignant disorders of the uterine cervix: A
placebo-controlled phase II study. Cancer Immunol Immunother.
63:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui Z and Huang L: Liposome-polycation-DNA
(LPD) particle as a carrier and adjuvant for protein-based
vaccines: Therapeutic effect against cervical cancer. Cancer
Immunol Immunother. 54:1180–1190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart TJ, Drane D, Malliaros J, Elmer H,
Malcolm KM, Cox JC, Edwards SJ, Frazer IH and Fernando GJ:
ISCOMATRIX adjuvant: An adjuvant suitable for use in anticancer
vaccines. Vaccine. 22:3738–3743. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hallez S, Simon P, Maudoux F, Doyen J,
Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, et al:
Phase I/II trial of immunogenicity of a human papillomavirus (HPV)
type 16 E7 protein-based vaccine in women with oncogenic
HPV-positive cervical intraepithelial neoplasia. Cancer Immunol
Immunother. 53:642–650. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Simon P, Buxant F, Hallez S, Burny A, Fayt
I, Anaf V and Noël JC: Cervical response to vaccination against
HPV16 E7 in case of severe dysplasia. Eur J Obstet Gynecol Reprod
Biol. 109:219–223. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frazer IH, Quinn M, Nicklin JL, Tan J,
Perrin LC, Ng P, O'Connor VM, White O, Wendt N and Martin J: Phase
1 study of HPV16-specific immunotherapy with E6E7 fusion protein
and ISCOMATRIX adjuvant in women with cervical intraepithelial
neoplasia. Vaccine. 23:172–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roman LD, Wilczynski S, Muderspach LI,
Burnett AF, O'Meara A, Brinkman JA, Kast WM, Facio G, Felix JC,
Aldana M and Weber JS: A phase II study of Hsp-7 (SGN-00101) in
women with high-grade cervical intraepithelial neoplasia. Gynecol
Oncol. 106:558–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Einstein MH, Kadish AS, Burk RD, Kim MY,
Wadler S, Streicher H, Goldberg GL and Runowicz CD: Heat shock
fusion protein-based immunotherapy for treatment of cervical
intraepithelial neoplasia III. Gynecol Oncol. 106:453–460. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Doorslaer K, Reimers LL, Studentsov
YY, Einstein MH and Burk RD: Serological response to an HPV16 E7
based therapeutic vaccine in women with high-grade cervical
dysplasia. Gynecol Oncol. 116:208–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sheets EE, Urban RG, Crum CP, Hedley ML,
Politch JA, Gold MA, Muderspach LI, Cole GA and Crowley-Nowick PA:
Immunotherapy of human cervical high-grade cervical intraepithelial
neoplasia with microparticle-delivered human papillomavirus 16 E7
plasmid DNA. Am J Obstet Gynecol. 188:916–926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garcia F, Petry KU, Muderspach L, Gold MA,
Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML and
Beach KJ: ZYC101a for treatment of high-grade cervical
intraepithelial neoplasia: A randomized controlled trial. Obstet
Gynecol. 103:317–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bagarazzi ML, Yan J, Morrow MP, Shen X,
Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et
al: Immunotherapy against HPV16/18 generates potent TH1 and
cytotoxic cellular immune responses. Sci Transl Med.
4:155ra1382012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Trimble CL, Morrow MP, Kraynyak KA, Shen
X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et
al: Safety, efficacy and immunogenicity of VGX-3100, a therapeutic
synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6
and E7 proteins for cervical intraepithelial neoplasia 2/3: A
randomised, double-blind, placebo-controlled phase 2b trial.
Lancet. 386:2078–2088. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alvarez RD, Huh WK, Bae S, Lamb LS Jr,
Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, et al: A
pilot study of pNGVL4a-CRT/E7 (detox) for the treatment of patients
with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
Gynecol Oncol. 140:245–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Trimble CL, Peng S, Kos F, Gravitt P,
Viscidi R, Sugar E, Pardoll D and Wu TC: A phase I trial of a human
papillomavirus DNA vaccine for HPV16+ cervical intraepithelial
neoplasia 2/3. Clin Cancer Res. 15:361–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riezebos-Brilman A, Regts J, Freyschmidt
EJ, Dontje B, Wilschut J and Daemen T: Induction of human papilloma
virus E6/E7-specific cytotoxic T-lymphocyte activity in
immune-tolerant, E6/E7-transgenic mice. Gene Ther. 12:1410–1414.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz
M, Boyd DA, He L, Chen PJ, Chen CH and Wu TC: Enhancement of
vaccinia vaccine potency by linkage of tumor antigen gene to gene
encoding calreticulin. Vaccine. 22:3993–4001. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Borysiewicz LK, Fiander A, Nimako M, Man
S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN,
Boursnell ME, et al: A recombinant vaccinia virus encoding human
papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy
for cervical cancer. Lancet. 347:1523–1527. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaufmann AM, Stern PL, Rankin EM, Sommer
H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner
U, et al: Safety and immunogenicity of TA-HPV, a recombinant
vaccinia virus expressing modified human papillomavirus (HPV)-16
and HPV-18 E6 and E7 genes, in women with progressive cervical
cancer. Clin Cancer Res. 8:3676–3685. 2002.PubMed/NCBI
|
|
42
|
Gutierrez CM Corona, Tinoco A, Navarro T,
Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli
G, Verde ML and Rosales R: Therapeutic vaccination with MVA E2 can
eliminate precancerous lesions (CIN 1, CIN 2 and CIN 3) associated
with infection by oncogenic human papillomavirus. Hum Gene Ther.
15:421–431. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
García-Hernández E, González-Sánchez JL,
Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, Jiménez R,
Reyes L, Morosoli G, Verde ML and Rosales R: Regression of
papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by
therapeutic vaccination with MVA E2 recombinant vaccine. Cancer
Gene Ther. 13:592–597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brun JL, Dalstein V, Leveque J, Mathevet
P, Raulic P, Baldauf JJ, Scholl S, Huynh B, Douvier S, Riethmuller
D, et al: Regression of high-grade cervical intraepithelial
neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol.
204:169.e1–e8. 2011. View Article : Google Scholar
|
|
45
|
Transgene: Transgene reports randomized
phase 2b data with its therapeutic HPV vaccine TG4001 in women with
CIN2/3 intraepithelial cervical neoplasia. https://www.transgene.fr/wp-content/uploads/PR/208_en.pdfNovember
11–2017
|
|
46
|
Sharma C, Dey B, Wahiduzzaman M and Singh
N: Human papillomavirus 16 L1-E7 chimeric virus like particles show
prophylactic and therapeutic efficacy in murine model of cervical
cancer. Vaccine. 30:5417–5424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kaufmann AM, Nieland JD, Jochmus I, Baur
S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder
B, Grubert T, et al: Vaccination trial with HPV16 L1E7 chimeric
virus-like particles in women suffering from high grade cervical
intraepithelial neoplasia (CIN 2/3). Int J Cancer. 121:2794–2800.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Souders NC, Sewell DA, Pan ZK, Hussain SF,
Rodriguez A, Wallecha A and Paterson Y: Listeria-based vaccines can
overcome tolerance by expanding low avidity CD8+ T cells capable of
eradicating a solid tumor in a transgenic mouse model of cancer.
Cancer Immun. 7:22007.PubMed/NCBI
|
|
49
|
Maciag PC, Radulovic S and Rothman J: The
first clinical use of a live-attenuated Listeria monocytogenes
vaccine: A Phase I safety study of Lm-LLO-E7 in patients with
advanced carcinoma of the cervix. Vaccine. 27:3975–3983. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kawana K, Adachi K, Kojima S, Taguchi A,
Tomio K, Yamashita A, Nishida H, Nagasaka K, Arimoto T, Yokoyama T,
et al: Oral vaccination against HPV E7 for treatment of cervical
intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific
mucosal immunity in the cervix of CIN3 patients. Vaccine.
32:6233–6239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stoler M, Bergeron C, Colgan T, Ferenczy
A, Herrington C, Kim K, Loening T, Schneider A, Sherman M, Wilbur
D, et al: Squamous cell tumours and precursors. WHO Classification
of tumours of the uterine cervix. IARC Press; pp. 172–181. 2014
|
|
52
|
Decker KM, McLachlin CM and Lotocki R;
Pan-canadian cervical cancer screening network monitoring program
performance working group, : Performance measures related to
colposcopy for canadian cervical cancer screening programs:
Identifying areas for improvement. J Obstet Gynaecol Can.
37:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kyrgiou M, Kalliala IE, Mitra A,
Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, Cruickshank M,
Arbyn M and Paraskevaidis E: Immediate referral to colposcopy
versus cytological surveillance for minor cervical cytological
abnormalities in the absence of HPV test. Cochrane Database Syst
Rev. 1:CD0098362017.PubMed/NCBI
|
|
54
|
Partridge EE, Abu-Rustum N, Giuliano A,
Massad S, McClure J, Dwyer M and Hughes M; National comprehensive
cancer network, : Cervical cancer screening. J Natl Compr Canc
Netw. 12:333–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Denis F, Cohen R, Stahl JP, Martinot A,
Dury V, Le Danvic M and Gaudelus J: Papillomavirus vaccination in
France according to 2008 to 2012 Vaccinoscopie(®) data.
Med Mal Infect. 44:18–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
